Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ENTX | PRESS-RELEASE | neutral | 5/10 | Entera Bio reported positive preclinical data at ENDO 2026 for two oral peptide programs: EB612 (hypoparathyroidism) sho | Jun 16, 2026 |
| VXRT | DEFA14A | neutral | 3/10 | Vaxart management filed additional definitive proxy materials (DEFA14A) urging shareholders to vote FOR all six of its d | Jun 16, 2026 |
| OPTH | 6-K | neutral | 3/10 | Optimi Health announced the launch of standardized 1mg and 2mg microdose psilocybin capsules for clinical research, exte | Jun 16, 2026 |
| CNTN | 8-K | neutral | 4/10 | Canton Strategic Holdings announced a $50 million share repurchase program authorized by the Board on June 11, 2026, and | Jun 16, 2026 |
| BIAF | 8-K | neutral | 2/10 | bioAffinity Technologies announced a July 21, 2026 webinar on veteran lung health screening, co-hosted with Philips, 4DM | Jun 16, 2026 |
| PVLA | 8-K | neutral | 2/10 | Palvella Therapeutics held its 2026 Annual Meeting on June 10, 2026, where shareholders approved an amendment to the 202 | Jun 16, 2026 |
| TEVA | CLUSTER | neutral | 2/10 | Two top executives at Teva (CEO and CFO) sold a combined $3.84M in shares over a one-week window, but the total represen | Jun 16, 2026 |
| CING | 8-K | bullish | 6/10 | Cingulate announced the USPTO issued its first company-owned U.S. patent (No. 12,653,791) for lead ADHD asset CTx-1301, | Jun 16, 2026 |
| OTLK | PRESS-RELEASE | bullish | 7/10 | Outlook Therapeutics announced FDA acceptance of its resubmitted BLA for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet AM | Jun 16, 2026 |
| BIOA | PRESS-RELEASE | neutral | 3/10 | BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 (NLRP3 inhibitor) | Jun 16, 2026 |
| ZEOX | 8-K | neutral | 2/10 | Zeo ScientifiX filed an 8-K announcing a product donation for a humanitarian pediatric burn reconstruction mission in Pe | Jun 16, 2026 |
| CMND | 6-K | neutral | 4/10 | Clearmind Medicine announced completion of dosing for all 24 participants in Part A of its Phase I/II clinical trial for | Jun 16, 2026 |
| ABOS | 8-K | neutral | 4/10 | Acumen Pharmaceuticals announced the nomination of two Enhanced Brain Delivery (EBD) development candidates, ACU301 and | Jun 16, 2026 |
| AVTX | 8-K | bullish | 6/10 | Avalo Therapeutics filed an 8-K announcing the advancement of AVTX-010, a long-acting next-generation anti-IL-1 mAb, wit | Jun 16, 2026 |
| HCWB | 8-K | bullish | 7/10 | HCW Biologics announced positive preliminary human data from the first two dose cohorts of its Phase 1 trial for HCW9302 | Jun 16, 2026 |
| IVVD | PRESS-RELEASE | neutral | 5/10 | Invivyd announced completion of enrollment in its Phase 3 LIBERTY trial comparing VYD2311 (monoclonal antibody) against | Jun 16, 2026 |
| HCWB | PRESS-RELEASE | bullish | 6/10 | HCW Biologics reported positive preliminary Phase 1 data for HCW9302 in alopecia areata: all three patients in the secon | Jun 16, 2026 |
| AVTX | PRESS-RELEASE | bullish | 5/10 | Avalo Therapeutics announced advancement of AVTX-010, a next-generation anti-IL-1β monoclonal antibody, with an IND subm | Jun 16, 2026 |
| PTCT | 8-K | neutral | 5/10 | PTC Therapeutics priced $500M of 0% convertible senior notes due 2031 (plus a $50M greenshoe) to refinance its 1.5% 2026 | Jun 16, 2026 |
| NBP | 6-K | bullish | 5/10 | NovaBridge Biosciences announced FDA Fast Track Designation for givastomig in first-line HER2-negative metastatic gastri | Jun 16, 2026 |
| PBH | 8-K | mixed | 6/10 | Prestige Consumer Healthcare completed its $1.045B acquisition of the Breathe Right brand from Foundation Consumer Brand | Jun 16, 2026 |
| ONMD | CLUSTER | bullish | 6/10 | CEO Aaron Green and director/10% owner Thomas Kosasa made open-market purchases totaling $121K over a 7-day window, repr | Jun 16, 2026 |
| ATHE | 6-K | neutral | 2/10 | Analysis based on filing metadata only, document content was unavailable. Alterity Therapeutics filed a Form 6-K furnish | Jun 16, 2026 |
| UNCY | EFFECT | bearish | 6/10 | Unicycive Therapeutics' universal shelf registration (S-3) was declared effective by the SEC on June 15, 2026, enabling | Jun 16, 2026 |
| NNVC | EFFECT | neutral | 3/10 | NanoViricides' resale registration statement (S-3) for 1,333,334 shares underlying warrants held by Orca Capital AG beca | Jun 16, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech priced a dilutive public offering of 22.7M shares at $3.75/share, expected to raise ~$85M, alongside a concurre | Jun 16, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech priced a dilutive public offering of 22.7M shares at $3.75/share, raising ~$85M in gross proceeds, with an addi | Jun 15, 2026 |
| ELVN | 144 | neutral | 2/10 | OrbiMed Capital LLC, acting as portfolio manager for The Biotech Growth Trust PLC, filed a Form 144 notice of intent to | Jun 15, 2026 |
| ELVN | 144 | bearish | 4/10 | OrbiMed Advisors LLC, a major healthcare investment firm and significant shareholder in Enliven Therapeutics, filed a Fo | Jun 15, 2026 |
| ELVN | 144 | neutral | 2/10 | OrbiMed Advisors LLC, on behalf of OrbiMed Genesis Master Fund, filed a Form 144 notice of intent to sell 9,086 shares o | Jun 15, 2026 |